Craft
Targovax

Targovax

Market Capitalization

KR222.2 M

2022-11-22

Targovax Summary

Company summary

Overview
Targovax is a clinical stage immuno-oncology company, which engages in the development of targeted immunotherapies for cancer patients. It is developing a peptide-based targeted immunotherapy platform for patients with RAS-mutated cancers; and a virus-based oncolytic immunotherapy platform based on engineered oncolytic viruses armed with potent immune-stimulating transgenes for patients with solid tumors. The Company’s product candidates include TG01, which is in Phase I/II clinical trial for the treatment of patients with resected adenocarcinoma of the pancreas; TG02 that is in Phase I clinical trial for the treatment of colorectal cancer; and ONCOS-102 that is in Phase I/II study for the treatment of mesothelioma, as well as for ovarian cancer and soft tissue sarcoma.
Type
Public
Status
Active
HQ
Lysaker, NO | view all locations
Website
http://targovax.com
Cybersecurity rating
Sectors

Key people

  • Damian Marron

    Damian Marron, Chairman of the Board

    • Diane Mellett

      Diane Mellett, Director

      • Robert Burns

        Robert Burns, Director

        • Erik Digman Wiklund

          Erik Digman Wiklund, Chief Business Officer

          LocationsView all

          3 locations detected

          • Lysaker, Viken HQ

            Norway

            Vollsveien 19

          • Esbo

            Finland

            Lars Soncks båge 14

          • Ullern, Oslo

            Norway

            2C Lilleakerveien

          Targovax Financials

          Summary financials

          Net income (Q3, 2022)
          (kr20.7M)
          Cash (Q2, 2022)
          kr125.8M
          EBIT (Q3, 2022)
          (kr20.3M)
          Enterprise value
          $186.5M

          Footer menu